Listen "Paul Taylor | Wise men say, only fools rush in… to Ozempic"
Episode Synopsis
Elvis may have been talking about love, but can’t the same be said for markets? GLP1 drugs like Ozempic’s success in the weight loss arena have disrupted the healthcare sector. Most notably ResMed, whose stock price plummeted on the back of predicted decreased demand. But where there is disruption and volatility, Paul Taylor sees opportunity. This month Paul talks about why taking an immediate view can cloud investors thinking and where he’s seen this all before. Got questions for us? Email [email protected] See why we’re an Aussie expert This episode was recorded 3 October 2023. Read our full disclaimer.See omnystudio.com/listener for privacy information.
More episodes of the podcast Fidelity Sound Bites
Asia: From factories to tech powerhouse
03/10/2025
Beyond human bias: The systematic advantage
14/08/2025
CIO Outlook: The global rewiring is underway
19/06/2025
The most volatile reporting season yet?
09/03/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.